Aug 18, 2025 • Benzinga
NEUTRAL
NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib - NewAmsterdam Pharma Co ( NASDAQ:NAMSW ) , NewAmsterdam Pharma Co ( NASDAQ:NAMS )
-- Filings both for the obicetrapib monotherapy and obicetrapib plus ezetimibe fixed-dose combination submitted to EMA by our partner, Menarini, for treatment of adults with primary hypercholesterolemia ( heterozygous familial and non-familial ) or mixed dyslipidemia --
Aug 07, 2025 • Motley Fool
NEUTRAL
NewAmsterdam ( NAMS ) Q2 Revenue Jumps 49%
NewAmsterdam Pharma ( NASDAQ:NAMS ) , a clinical-stage biopharmaceutical company focused on developing oral therapies for cardiometabolic diseases, delivered its Q2 2025 earnings report on August 6, 2025. The most important news from the release was GAAP revenue of $19.1 million, a significant ...
Aug 06, 2025 • Zacks Commentary
NEUTRAL
NewAmsterdam Pharma Company N.V. ( NAMS ) Reports Q2 Loss, Tops Revenue Estimates
NewAmsterdam Pharma Company N.V. (NAMS) delivered earnings and revenue surprises of +71.15% and +486.19%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Aug 06, 2025 • GlobeNewswire
NEUTRAL
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
-European marketing authorization application on track in ...
Jul 30, 2025 • GlobeNewswire
NEUTRAL
NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer's Disease Biomarkers at AAIC 2025
-- Pre-specified analysis shows obicetrapib significantly reduced absolute levels of plasma p-tau217, a key biomarker of Alzheimer's disease pathology, in both the full analysis set ( p=0.0019 ) and in ApoE4 carriers ( p=0.0215 ) , supporting CETP inhibition as a potential novel, upstream ...
Jul 30, 2025 • Benzinga
NEUTRAL
NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer's Disease Biomarkers at AAIC 2025 - NewAmsterdam Pharma Co ( NASDAQ:NAMSW ) , NewAmsterdam Pharma Co ( NASDAQ:NAMS )
-- Pre-specified analysis shows obicetrapib significantly reduced absolute levels of plasma p-tau217, a key biomarker of Alzheimer's disease pathology, in both the full analysis set ( p=0.0019 ) and in ApoE4 carriers ( p=0.0215 ) , supporting CETP inhibition as a potential novel, upstream ...